汇宇制药：公司产品注射用紫杉醇(白蛋白结合型)获得葡萄牙和英国上市许可

Core Viewpoint - The company has received marketing approvals for its injectable paclitaxel (albumin-bound) from regulatory authorities in Portugal and the UK, indicating a significant step in expanding its product offerings in the oncology market [1] Group 1: Product Approval - The company's subsidiaries, Seacross (Europe) Pharma Ltd. and Seacross Pharmaceuticals Ltd., have obtained marketing licenses for injectable paclitaxel from the Portuguese Medicines and Health Products Regulatory Authority and the UK Medicines and Healthcare products Regulatory Agency [1] - The injectable paclitaxel is primarily indicated for the treatment of adult patients with metastatic breast cancer, pancreatic adenocarcinoma, and non-small cell lung cancer [1] Group 2: Market Expansion - The product has already received marketing authorization in the UK, Portugal, Denmark, Netherlands, Ireland, Finland, and Sweden [1] - Additionally, registration applications have been submitted in Italy, France, Spain, and seven other countries, indicating a proactive approach to market expansion [1]